Viscoelastic Hemostatic Assays and Platelet Function Testing in Patients with Atherosclerotic Vascular Diseases.
Matej SamošIngrid ŠkorňováTomáš BolekLucia StančiakováBarbora KorpallováPeter GalajdaJan StaskoPeter KubiszMarián MokáňPublished in: Diagnostics (Basel, Switzerland) (2021)
Platelets play crucial role in acute vascular atherosclerotic diseases, including myocardial infarction and stroke. Additionally, platelet aggregation is a key target of antiplatelet agents, forming the keystone of pharmacotherapy of various atherosclerotic cardiovascular diseases. Thromboelastography and thromboelastometry, representing currently available viscoelastic hemostatic assays (VHA), are designed as whole blood, real-time analyzers of clot formation and clot resolution. These assays could, in theory, overcome some limitations of currently available platelet function testing assays. This article reviews the current experience with the use of VHA for platelet function testing and for monitoring of the response to antiplatelet therapy.
Keyphrases
- antiplatelet therapy
- high throughput
- cardiovascular disease
- acute coronary syndrome
- percutaneous coronary intervention
- liver failure
- coronary artery disease
- randomized controlled trial
- metabolic syndrome
- respiratory failure
- single molecule
- cardiovascular events
- single cell
- blood brain barrier
- acute respiratory distress syndrome
- brain injury